Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nasal Spray Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Long-term Use of Proton Pump Inhibitors May Cause Vitamin B12 Deficiency in the Institutionalized Elderly

NCT00843453
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
blood collection, treatment (cyanocobalamin nasal spray)
Other · Drug
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 89 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Manchester, Maryland • Timonium, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2009 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults

NCT02609945
View directory record Official record
Conditions
Migraine
Interventions
zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 27, 2026, 11:14 PM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

The Role of Vasopressin in the Social Deficits of Autism

NCT01962870
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Vasopressin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 4 Interventional Results available

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777
View directory record Official record
Conditions
Migraine
Interventions
Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nursing Attitudes Towards SUD

NCT05218681
View directory record Official record
Conditions
Substance Use Disorders, Stigma, Social
Interventions
Unit-based "Person First" Anti-stigma Awareness Rounds, Individual Text-based Messaging
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

NCT00118729
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets

NCT03898986
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated influenza vaccine (LAIV4), Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 20 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

To Study GSP 301 in Patients With Seasonal Allergic Rhinitis

NCT02318303
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
GSP 301-1 NS (QD), GSP 301-2 NS (BID), GSP 301 Placebo NS, Olopatadine HCl-1 NS (QD), Olopatadine HCl-2 NS (BID), Mometasone Furoate-1 NS (QD), Mometasone Furoate-2 NS (BID)
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
12 Years and older
Enrollment
1,111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
43
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 27, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional Results available

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

NCT03635996
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System
Drug · Device
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT06013241
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Tucson, Arizona • Roseville, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

NCT06063330
View directory record Official record
Conditions
COVID-19, Infectious Disease, Symptomatic COVID-19 Infection Laboratory-Confirmed, SARS CoV 2 Infection
Interventions
RQ-001, Placebo
Combination Product · Other
Lead sponsor
Red Queen Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE

NCT03275922
View directory record Official record
Conditions
Migraine
Interventions
Placebo ZNS, ZNS
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
47
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 27, 2026, 11:14 PM EDT
Recruiting Phase 2 Interventional

Nasal Obstruction With Oxymetazoline and Corticosteroids

NCT06830109
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Oxymetazoline Nasal Spray, Budesonide nasal spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

NCT04364802
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
Povidone-Iodine Nasal Spray and Gargle
Drug
Lead sponsor
Nikita Gupta
Other
Eligibility
18 Years to 99 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

NCT01417078
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional Results available

Comparison of Nasal Steroids After FESS in CRSwNP

NCT02194062
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
fluticasone nasal spray, Budesonide head upright, Budesonide head forward
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 4 Interventional

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

NCT00806754
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 27, 2026, 11:14 PM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

NCT06358651
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

NCT00699556
View directory record Official record
Conditions
Alcohol Drinking
Interventions
21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Sep 27, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Brain Dynamics of Oxytocin

NCT01834261
View directory record Official record
Conditions
Brain Dynamics in Healthy Adults
Interventions
Syntocinon Nasal Spray, 40IU, Syntocinon Placebo Formulation, 40IU
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Cambridge, Massachusetts • Charlestown, Massachusetts • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 27, 2026, 11:14 PM EDT